Sickle Cell Disease Treatment Market Report Scope & Overview:

The Sickle Cell Disease Treatment Market was valued at USD 3.28 Billion in 2025 and is expected to reach USD 13.10 Billion by 2035, growing at a CAGR of 14.84% from 2026 to 2035.

Sickle Cell Disease is a hereditary condition affecting the red blood cells and marked by an abnormality of hemoglobin causing the red blood cells to have a sickle shape due to which there is premature destruction of the red blood cells, blood deficiency, and restriction of blood circulation. The methods for treating sickle cell disease have undergone major changes from purely symptomatic treatment to potentially curative therapies as the conventional treatment involves the use of medications such as hydroxyurea for reduction in pain crises and blood transfusion for managing complications and preventing strokes. The market will continue to be driven by increasing incidences of sickle cell disease globally.

The United States Centers for Medicare and Medicaid Services implemented its Cell and Gene Therapy Access Model in January 2025, making expensive, potentially curative therapies more accessible by delivering budget predictability to Medicaid agencies covering advanced sickle cell disease treatments including gene-editing therapies.

Market Size and Forecast

• Market Size in 2026E: USD 3.77 Billion
• Market Size by 2035: USD 13.10 Billion
• CAGR: 14.84% from 2026 to 2035
• Fastest Growing Region: Asia Pacific
• Largest Region: North America

To Get more information Sickle Cell Disease Treatment Market - Request Free Sample Report

Sickle Cell Disease Treatment Market Trends

• A growing focus on curative approaches, particularly stem cell and gene therapies, signals strong potential for long-term treatment progress.
• Emerging pipeline therapies show promise in reducing overall disease burden and may lead to improved reimbursement scenarios.
• Expanding newborn screening programs and improved diagnostic capabilities continue supporting earlier disease identification and intervention.
• Integration of digital health tools continues supporting improved disease management and patient monitoring capability.
• Government-led awareness campaigns and advocacy programs continue expanding patient access to specialized treatment resources.

The United States Sickle Cell Disease Treatment Market Outlook

The United States Sickle Cell Disease Treatment Market was valued at USD 1.14 Billion in 2025 and is expected to reach USD 4.60 Billion by 2035, growing at a CAGR of 15.00% from 2026 to 2035.

The dominance of the market in the United States continues being attributed to better access to sickle cell disease treatment, potential pipeline candidates, strong government support, and rising collaborations to improve disease treatment. As financial capacity improves, individuals are more likely to access specialized healthcare facilities, undergo regular diagnostic testing, and afford long-term treatment plans, including higher-cost therapies such as disease-modifying drugs or gene-based interventions, throughout the country's largest healthcare systems.

The Global Alliance of Sickle Cell Disease Organizations announced its World Sickle Cell Awareness Day theme in June 2025, amplifying the voices of individuals and families affected by sickle cell disease and reinforcing continued advocacy for expanded treatment access across American healthcare systems.

Sickle Cell Disease Treatment Market Segment Analysis

• By Treatment Modality, the blood transfusion segment held approximately 44.10% share in 2025, while the gene-editing therapies segment is the fastest growing, with a CAGR of approximately 17.34%.
• By Route of Administration, the oral segment held the largest share in 2025, while the parenteral segment is the fastest growing.
• By Age Group, the adult segment held the largest share in 2025, while the pediatric segment is the fastest growing.
• By End-User, the hospitals segment held the largest share in 2025, while the specialty clinics segment is the fastest growing.

By Treatment Modality, blood transfusion segment dominates the sickle cell disease treatment market, gene-editing therapies grows fastest

The Blood Transfusion segment held approximately 44.10% of total market revenue in 2025, owing to its availability and comparatively low risk relative to other treatment options for sickle cell disease patients. That established accessibility and safety profile continues to keep blood transfusion firmly at the top of the broader treatment modality segmentation, with hydroxyurea and bone marrow transplant continuing to represent substantial additional treatment categories.

The Gene-Editing Therapies segment is projected to grow at the fastest CAGR of approximately 17.34% during the forecast period, reflecting early adoption of curative options including Casgevy and Lyfgenia that represent a genuine shift from symptom management toward disease-modifying and potentially curative intervention. Rising clinical adoption of these gene-editing approaches continues pushing this treatment modality category's growth rate ahead of the broader treatment modality segmentation.

By Route of Administration, oral segment dominates the sickle cell disease treatment market, parenteral grows fastest

The Oral segment held the largest share of the route of administration segmentation in 2025, favored for its convenience and suitability for long-term disease management medications including hydroxyurea that patients take on an ongoing basis. That established convenience advantage continues to keep oral administration firmly at the top of the broader route of administration segmentation across the majority of chronic disease management protocols.

The Parenteral segment is projected to grow at the fastest CAGR during the forecast period, supported by rising adoption of infusion-based and gene-editing therapies that require intravenous or specialized delivery methods unavailable through oral administration. Rising clinical adoption of these advanced curative and disease-modifying therapies continues pushing this route of administration category's growth rate ahead of the broader route of administration segmentation.

By Age Group, adult segment dominates the sickle cell disease treatment market, pediatric grows fastest

The Adult segment held the largest share of the age group segmentation in 2025, accounting for nearly two-fifths of total market share, reflecting the substantial adult sickle cell disease patient population requiring ongoing, long-term disease management. That substantial, sustained adult patient population continues to keep this age group firmly at the top of the broader age group segmentation across nearly every major regional healthcare market worldwide.

The Pediatric segment is projected to grow at the fastest CAGR during the forecast period, supported by expanding newborn screening programs that continue improving early disease identification and enabling earlier therapeutic intervention. Rising pediatric diagnosis rates continue pushing this age group category's growth rate ahead of the broader age group segmentation.

By End-User, hospitals segment dominates the sickle cell disease treatment market, specialty clinics grows fastest

The Hospitals segment held the largest share of the end-user segmentation in 2025, supported by the rising prevalence of patient visits requiring comprehensive clinical infrastructure for complex sickle cell disease management, including transfusion services and gene therapy administration. That established clinical infrastructure requirement continues to keep hospitals firmly at the top of the broader end-user segmentation.

The Specialty Clinics segment is projected to grow at the fastest CAGR during the forecast period, as dedicated sickle cell disease treatment centers continue expanding to provide focused, specialized care outside general hospital settings. Rising investment in specialized sickle cell disease treatment infrastructure continues pushing this end-user category's growth rate ahead of the broader end-user segmentation.

Regional Analysis

North America Sickle Cell Disease Treatment Market Insights

North America currently dominates the global Sickle Cell Disease Treatment Market, holding a significant market share supported by sophisticated healthcare infrastructure, higher awareness regarding the disease, and strong government support across the region. The Cell and Gene Therapy Access Model implemented by the United States Centers for Medicare and Medicaid Services continued making expensive, potentially curative therapies more accessible throughout the year.

The United States accounted for roughly 85.10% of regional revenue, reflecting its concentration of leading pharmaceutical companies and advanced sickle cell disease treatment options. Canada contributed a smaller but steadily growing share of regional revenue, supported by its own expanding gene therapy access programs, keeping North America firmly ahead of every other region in this market.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Sickle Cell Disease Treatment Market Insights

The Sickle Cell Disease Treatment Market share of Europe was considerable in 2025, owing to the presence of well-developed health insurance policies and pharmaceutical research facilities in the region. Germany contributed about 27.20% to the revenue of the market in the region due to its presence of biopharmaceutical companies and well-developed healthcare infrastructure.

France, the United Kingdom, and Italy followed a broadly similar trajectory, as continued investment in gene therapy access extended sickle cell disease treatment demand across the continent's largest healthcare markets. Continued regulatory support for advanced cell and gene therapy approvals is expected to keep supporting steady European demand through the remainder of the forecast period.

Asia Pacific Sickle Cell Disease Treatment Market Insights

Asia Pacific was the fastest-growing region in the global Sickle Cell Disease Treatment Market, supported by government initiatives including India's National Sickle Cell Anaemia Elimination Mission, improved screening, and rising healthcare investment across the region's largest and most populous economies. Rising healthcare spending and patient awareness continued driving regional demand at a pace considerably faster than more mature Western markets.

India accounted for roughly 36.40% of regional revenue, supported by its large affected population and expanding government-led screening and treatment programs. China and Nigeria-adjacent African markets contributed additional demand context through their own substantial sickle cell disease burden, reinforcing Asia Pacific's position as the clear growth leader in this market.

MEA & Latin America Sickle Cell Disease Treatment Market Insights

In 2025, Middle East and Africa experienced high rates of uptake of treatments for sickle cell disease because the region had many cases of sickle cell disease. It was characterized by increasing initiatives in disease screening and treatment through governments in the Gulf States. Around 26.30% of revenues in the region came from the UAE due to healthcare modernization efforts and increased demand for sickle cell disease treatment solutions.

Latin America expanded at a comparable pace, led by Brazil at roughly 37.10% of regional revenue, where growing healthcare infrastructure investment continued to support category growth. Mexico and Argentina followed a similar trajectory as regional sickle cell disease treatment access expanded further through the remainder of the forecast period.

Growth Drivers: Gene Therapy Innovation and Expanding Newborn Screening Programs

The rising prevalence of sickle cell disease globally, supported by expanding newborn screening programs and improved diagnostic capabilities, continues to be the central force behind sickle cell disease treatment market growth. Growing investments in research and development, alongside advancements in gene and cell therapies, continue accelerating the availability of innovative treatment options across nearly every major regional healthcare market worldwide.

Supportive government policies, increased healthcare funding, and initiatives including expanded Medicaid budget predictability continue significantly augmenting market growth. Increasing disposable incomes, particularly in emerging economies, continue enabling more patients to seek timely and advanced treatment, supporting sustained market expansion through the forecast period.

Restraints: High Gene Therapy Costs and Limited Treatment Center Access

The exorbitant expense associated with the gene editing treatment therapies, such as Casgevy and Lyfgenia, remains an impediment in the uptake of these treatments by health care systems and patients with limited payment systems. This remains a barrier in making the treatment available to well-endowed health care systems and financially capable individuals.

Limited availability of specialized treatment centers capable of administering complex gene therapy and bone marrow transplant procedures continues restricting patient access, particularly in regions with high sickle cell disease prevalence but underdeveloped healthcare infrastructure. That access limitation continues requiring sustained investment in specialized treatment center development.

Opportunities: Curative Therapy Pipeline Expansion and Emerging Market Access Development

Further development of the clinical pipeline of gene and cell therapies that have potential to cure disease represents great opportunity for those pharmaceutical companies able to meet the needs of patients who do not want a lifetime of symptomatic treatment. Pharmaceutical companies that can commercialize such curative therapies will be able to increase their market share.

Expanding sickle cell disease treatment access across emerging markets with substantial disease burden, including regions across Africa and South Asia, presents a further significant growth avenue. Companies capable of establishing affordable, scalable treatment infrastructure in these developing markets stand to capture meaningful new revenue streams through 2035.

Recent Developments:

• 2025: Vertex Pharmaceuticals continued expanding access to Casgevy, its gene-editing therapy developed in partnership with CRISPR Therapeutics, strengthening treatment center capacity to administer this curative sickle cell disease intervention.
• 2025: Pfizer continued advancing its sickle cell disease treatment portfolio, including Oxbryta, targeting patients requiring disease-modifying therapy to reduce pain crises and complications.
• 2025: Novartis continued expanding access to Adakveo, its crizanlizumab therapy for sickle cell disease, strengthening its position serving patients seeking to reduce the frequency of vaso-occlusive pain crises.

Sickle Cell Disease Treatment Market key players are:

• Novartis AG
• Sanofi S.A.
• Pfizer Inc.
• Vertex Pharmaceuticals Incorporated
• CRISPR Therapeutics AG
• AstraZeneca plc
• Eli Lilly and Company
• bluebird bio, Inc.
• Novo Nordisk A/S
• Emmaus Life Sciences, Inc.
• Fulcrum Therapeutics, Inc.
• Editas Medicine, Inc.
• Beam Therapeutics Inc.
• Agios Pharmaceuticals, Inc.
• Global Blood Therapeutics, Inc.
• Roche Holding AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Johnson & Johnson
• GlaxoSmithKline plc

Sickle Cell Disease Treatment Market Report Scope :